Celltrion, Inc (068270) Fair Value & Analysis
Healthcare · KR · Market cap 40.3T KRW
Fair value as of: Aug 13, 2026
From 26 valuation models · updated today
Fair value updated Aug 13, 2026, revised from 76,325 KRW to 74,519 KRW (−2.4%) since Jul 18, 2026. Share price +16.9% over the past month.
Below-average quality, and screening another 63% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (95,951 KRW). The favourable scenario is already priced in.
- Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (53,086 KRW to 95,951 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range 130,526 KRW – 325,750 KRW · fair‑value band 53,086 KRW – 95,951 KRW · the 202,000 KRW price screens above the 74,519 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Celltrion, Inc (068270) currently trades at 202,000 KRW, while our model-based Fair Value estimate is 74,519 KRW, implying the stock looks roughly 63.1% overvalued today. The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Celltrion, Inc generated revenue of 4.5T KRW at a net margin of 28.4%. Revenue grew 36.0% year over year. It earns a return on equity of 7.3%. Net debt stands at 2.6T KRW. Fundamentals as of Aug 13, 2026
Our scenario range runs from 53,086 KRW (bear case) to 95,951 KRW (bull case); at 202,000 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 15% below its 52-week high and 35% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -47% fair-value upside, at -63%, 068270 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (135,611 KRW) versus Dividend Discount (11,534 KRW). Highest evidence: Growth DCF (80).
Notify me when 068270 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 47 · Market factors (momentum, volatility) 50
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products.
Full company description
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease; Vegzelma for metastatic colorectal cancer and non-small cell lung cancer; Omlyclo for Asthma and urticaria; Eydenzelt for diabetic macular edema and wet age-related macular degeneration; Steqeyma for psoriasis and inflammatory bowel disease; Stoboclo/Osenvelt for osteoporosis; Avtozma for rheumatoid arthritis and active systemic juvenile idiopathic arthritis; Zymfentra for inflammatory bowel disease; and Regkirona for COVID-19, as well as CT-G07 for HIV/AIDS and Donerion Patch for Alzheimer's dementia symptoms. The company is also developing biosimilars, which are in Phase 3 clinical trials include CT-P44 for multiple myeloma, CT-P51 for melanoma and lung cancer, CT-P53 for multiple sclerosis, and CT-P55 for psoriasis, as well as CT-G20 for hypertrophic cardiomyopathy. It distributes its products in approximately 100 countries, including the United States and Europe. The company was founded in 2002 and is headquartered in Incheon, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Celltrion, Inc reported revenue of 4.2T KRW in FY2025 versus 1.9T KRW in FY2021, a compound +21.5%/yr. Reported net income was 1.0T KRW in FY2025, compounding +15.5%/yr from FY2021.
of which total revenue +24.3 pp · buybacks/dilution −3.0 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
068270 screens 63% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 600 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $525.73 | $278.78 | -47% |
| Regeneron Pharmaceuticals, Inc REGN | $797.99 | $594.40 | -26% |
| Samsung Biologics Co 207940 | 1,549,000 KRW | 1,055,793 KRW | -32% |
| WuXi Biologics (Cayman) Inc 2269 | HK$45.70 | HK$30.58 | -33% |
| Innovent Biologics, Inc 1801 | HK$95.55 | HK$19.68 | -79% |
| Genmab A/S GMAB | kr 2,037 | kr 250.07 | -88% |
| Sino Biopharmaceutical Limited 1177 | HK$4.87 | HK$3.37 | -31% |
| RemeGen Co 688331 | ¥131.87 | ¥23.19 | -82% |
| ALTEOGEN Inc 196170 | 317,500 KRW | 39,476 KRW | -88% |
| Biocon Limited BIOCON | ₹427.40 | ₹52.10 | -88% |
Compare Celltrion, Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Celltrion, Inc (068270) overvalued or undervalued?
What is the fair value of 068270?
What is the quality score of 068270?
What is the revenue of Celltrion, Inc (068270)?
What is the net profit margin of 068270?
Does Celltrion, Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Celltrion, Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.